Fradley Michael G, Barrett Conor D, Clark John R, Francis Sanjeev A
Divisions of Cardiology (Drs. Barrett, Fradley, and Francis) and Hematology and Oncology (Dr. Clark), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114.
Tex Heart Inst J. 2013;40(4):472-6.
The antimetabolite chemotherapeutic agent 5-fluorouracil is used to treat a variety of cancers. Although 5-fluorouracil is generally well tolerated, its toxicity profile includes potential cardiac ischemia, vasospasm, arrhythmia, and direct myocardial injury. These actual or potential toxicities are thought to resolve upon cessation of the medication; however, information about the long-term cardiovascular effects of therapy is not sufficient. We present the case of a 58-year-old man who had 2 ventricular fibrillation cardiac arrests, with evidence of coronary vasospasm and myocarditis, on his 4th day of continuous infusion with 5-fluorouracil. External defibrillation and cessation of the 5-fluorouracil therapy resolved the patient's electrocardiographic abnormalities. In addition to reporting the clinical manifestations of 5-fluorouracil-associated cardiotoxicity in our patient, we discuss management challenges in patients who develop severe 5-fluorouracil-induced ventricular arrhythmias.
抗代谢化疗药物5-氟尿嘧啶用于治疗多种癌症。尽管5-氟尿嘧啶通常耐受性良好,但其毒性反应包括潜在的心脏缺血、血管痉挛、心律失常和直接心肌损伤。这些实际或潜在的毒性被认为在停药后会消退;然而,关于该治疗长期心血管影响的信息并不充分。我们报告一例58岁男性患者,在持续输注5-氟尿嘧啶的第4天发生2次心室颤动心脏骤停,有冠状动脉痉挛和心肌炎的证据。体外除颤和停用5-氟尿嘧啶治疗使患者的心电图异常得以缓解。除了报告我们患者中5-氟尿嘧啶相关心脏毒性的临床表现外,我们还讨论了发生严重5-氟尿嘧啶诱导的室性心律失常患者的管理挑战。